Global Orphan Diseases Partnering 2012-2018: Latest Deal Trends, Players and Financials Analysis - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Sep 25, 2018--The “Global Orphan Diseases Partnering 2012-2018: Deal trends, players and financials” report has been added to ResearchAndMarkets.com’s offering.
Global Orphan Diseases Partnering 2012 to 2018 provides the full collection of Orphan Diseases disease deals signed between the world’s pharmaceutical and biotechnology companies since 2012.
Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor’s product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.
The report takes readers through the comprehensive Orphan Diseases disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Orphan Diseases deals.
The report presents financial deal terms values for Orphan Diseases deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.
Report scopeTrends in Orphan Diseases dealmaking in the biopharma industry since 2012 Analysis of Orphan Diseases deal structure Access to headline, upfront, milestone and royalty data Access to hundreds of Orphan Diseases deal contract documents Comprehensive access to over 3500 Orphan Diseases deal records The leading Orphan Diseases deals by value since 2012 Most active Orphan Diseases dealmakers since 2012
Available deals and contracts are listed by:Headline value Upfront payment value Royalty rate value Stage of development at signing Deal component type Technology type Specific therapy indication
Key Topics Covered:
Chapter 1 - Introduction
Chapter 2 - Trends in Orphan Diseases dealmaking
2.2. Orphan Diseases partnering over the years
2.3. Orphan Diseases partnering by deal type
2.4. Orphan Diseases partnering by industry sector
2.5. Orphan Diseases partnering by stage of development
2.6. Orphan Diseases partnering by technology type
2.7. Orphan Diseases partnering by therapeutic indication
Chapter 3 - Financial deal terms for Orphan Diseases partnering
3.2. Disclosed financials terms for Orphan Diseases partnering
3.3. Orphan Diseases partnering headline values
3.4. Orphan Diseases deal upfront payments
3.5. Orphan Diseases deal milestone payments
3.6. Orphan Diseases royalty rates
Chapter 4 - Leading Orphan Diseases deals and dealmakers
4.2. Most active in Orphan Diseases partnering
4.3. List of most active dealmakers in Orphan Diseases
4.4. Top Orphan Diseases deals by value
Chapter 5 - Orphan Diseases contract document directory
5.2. Orphan Diseases partnering deals where contract document available
Chapter 6 - Orphan Diseases dealmaking by therapeutic target
6.2. Deals by Orphan Diseases therapeutic target
Appendix 1 - Directory of Orphan Diseases deals by company A-Z 2012 to 2018
Appendix 2 - Directory of Orphan Diseases deals by deal type 2012 to 2018
Appendix 3 - Directory of Orphan Diseases deals by stage of development 2012 to 2018
Appendix 4 - Directory of Orphan Diseases deals by technology type 2012 to 2018For more information about this report visit https://www.researchandmarkets.com/research/wnmwzf/global_orphan?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20180925005920/en/
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 09/25/2018 11:56 AM/DISC: 09/25/2018 11:56 AM